Lindbrook Capital’s Alto Neuroscience ANRO Stock Holding History

Lindbrook Capital’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-35	Closed	-$400	–	2925
2024 Q3	$400	Buy	+35	New	+$428	﹤0.01%	2721

Other funds holding ANRO

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Lindbrook Capital's ANRO Position: Q4 2024 in Review

Lindbrook Capital sold out of Alto Neuroscience (ANRO) in Q4 2024, closing a stake of 35 shares — an estimated $400 sold.

Lindbrook Capital first reported a position in ANRO in Q3 2024 and held it in 1 quarter. The position peaked at $400 in Q3 2024. 77 funds tracked by Wall St. Rank hold ANRO as of Q4 2024.

Lindbrook Capital reported no remaining Alto Neuroscience position as of Q4 2024 after selling out during the quarter.
Lindbrook Capital sold 35 Alto Neuroscience shares in Q4 2024, an estimated $400.
Lindbrook Capital first reported a position in Alto Neuroscience in Q3 2024 and held it in 1 quarter.
Lindbrook Capital's Alto Neuroscience position peaked at $400 in Q3 2024.
77 funds tracked by Wall St. Rank held Alto Neuroscience as of Q4 2024.

Based on Lindbrook Capital's 13F filing for Q4 2024, filed 6 Feb 2025.